Eagle Pharmaceuticals (EGRX) announced the appointment of Christopher Krawtschuk as CFO of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk’s appointment, Steven Ratoff stepped down from his role as interim CFO and will remain as a director on the Company’s board of directors. Most recently, Mr. Krawtschuk served as CFO and Treasurer of bluebird bio.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EGRX:
- Eagle Pharmaceuticals Implements Stockholder Rights Plan
- Eagle Pharmaceuticals adopts limited duration stockholder rights plan
- Eagle Pharmaceuticals Navigates Financial Uncertainty and Defaults
- Eagle Pharmaceuticals says in default under credit agreement
- Eagle Pharmaceuticals delays annual report on Form 10-K filing